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ABSTRACT 
 
The cornea is the outermost layer of the eye, which is responsible for transmitting 95% of the 
incident light to the retina for vision and provides 70% of the focusing power of the eye. 
Corneal disease is a primary cause of blindness worldwide. Replacing the pathologic cornea 
with a donor cornea is the most accepted treatment, but there is a severe shortage of donor 
tissue, resulting in an extensive waiting list for transplantation of over 10 million people. In 
this thesis, we worked on the development of artificial corneas to solve the donor shortage 
issue. Although an artificial cornea made from carbodiimide crosslinked recombinant human 
collagen developed within our lab was successfully transplanted into 10 patients in a clinical 
trial, this material was not tough enough to withstand severe disease conditions where 
inflammation is present, and where enzymes secreted can cause premature implant 
degradation. To improve mechanical strength and material stability, a secondary network of  
2-methacryloyloxyethyl phosphorylcholine (MPC) biopolymer was incorporated within the 
collagen hydrogel, forming an interpenetrating network (IPN). High resolution transmission 
electron microscopy showed that the implants comprised loosely bundled collagen filaments. 
X-ray scattering further revealed that the collagen fibrils within the implants were uniaxially 
oriented, whereas a biaxial alignment is present within the human cornea. This fibril 
arrangement resulted in highly transparent implants that transmitted virtually all incoming 
light of visible spectra together with a large proportion of UV light. This study is critical in a 
sense that it strongly suggests that all patients transplanted with this artificial cornea should 
take the precaution to use UV protection prior to re-growth of the epithelium, which is known 
to absorb harmful UV rays. To determine the utility of the implants for clinical use, we 
showed that they could be cut with a femtosecond laser. Laser excision of diseased patient 
tissue avoids damage to the surrounding healthy tissue, thereby circumventing excessive, 
undesirable inflammatory responses associated with the manual surgical technique while the 
cutting of a matched implant allows for precise host-graft apposition and seamless 
regeneration. We also showed that the surface of the implants could be modified to enhance 
rapid and stable epithelial growth. We demonstrated that we could pattern the implants 
surfaces using microcontact printing with fibronectin as “ink”. The dimensions of the 
patterned stripes were important in controlling corneal epithelial cell behavior including 
proliferation. This is important to ensure rapid wound healing and hence, an overall superior 
clinical outcome.   
 
In all of the above materials, the collagen was crosslinked with N-(3-dimethylaminopropyl)-
N'-ethylcarbodiimide (EDC)/N-hydroxysuccinimide (NHS). EDC is a zero-length crosslinker 
and while it produces a sufficiently robust hydrogel for clinical implantation, suturability was 
still an issue. To enhance suturability, we evaluated the effects of an epoxy-based crosslinker, 
1,4-Butanediol diglycidyl ether (BDDGE), which has been shown to result in collagen 
hydrogels with enhanced elasticity. As neuronal ingrowth into the hydrogels and epithelial 
cell coverage are important considerations in achieving regeneration, we examined the effects 
  
of incorporation of short cell adhesive laminin peptides within the BDDGE-crosslinked 
hydrogels. We showed that incorporation of YIGSR and IKVAV peptides enhanced the 
proliferation of corneal epithelial cells and neuronal progenitor cells, respectively.  
 
Although artificial corneas made from collagen have been successfully tested in the clinic, 
animal-derived collagens, in general, come from very heterogeneous sources and carry a risk 
of pathogen transmission. Use of recombinant human collagens mitigates those issues but just 
like native collagens; they are large macromolecules, relatively inert and therefore difficult to 
chemically alter to design in new functionalities. They are difficult and hence expensive to 
produce. Collagen-like peptides (CLP), also known as collagen mimetic peptides, are 
relatively short sequences that have been designed to replicate and reproduce the function of 
full-length collagen. We examined the safety and efficacy of one such CLP that we had 
conjugated to polyethylene glycol-maleimide (PEG) as implants for promoting corneal 
regeneration in mini-pig models. This CLP-PEG implants promoted the regeneration of 
corneal epithelial and stromal cells from endogenous progenitors, as well as cornea nerves to 
form a stable neo-cornea. The use of fully synthetic materials that can be produced under a 
tightly controlled environment such as CLP-PEG mitigates safety issues associated with 
native collagen from animal or human sources, as well as makes production sufficiently cost-
effective to allow for future scale-up. 
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1 INTRODUCTION 
REGENERATIVE MEDICINE  
Regeneration or regrowth of lost or damaged tissues or organs is a part of life. An adult 
human body has stem cells in virtually every organ that, in theory, have the capacity to 
replace themselves. Although organs like the liver and skin do have the regenerative 
capacity, in most organs, however, the resident stem cells on their own are not 
sufficient to achieve the repair needed to prevent organ failure in cases of disease or 
extensive damage. Hence, in humans, regeneration is limited.  
Regenerative Medicine has been defined as a “branch of medicine that develops 
methods to regrow, repair or replace damaged or diseased cells, organs or tissues[1]”. 
As such, it includes the science of developing therapeutic stem cells and tissue 
engineering. This field holds the promise of restoring damaged tissues and organs by 
stimulating the body's own repair mechanisms to functionally heal previously 
irreparable tissues or organs. 
If the patients’ own endogenous or autologous cells were used therapeutically, then 
immune rejection issues would be circumvented. The use of acellular biomaterials that 
can promote endogenous regeneration is an option that has been gaining momentum. 
The use of such an approach alleviates the need for expensive cleanrooms that are 
needed for cell expansion[2]. In this thesis, I will mostly discuss the regenerative 
approaches of making artificial cornea using biomaterials that promote endogenous 
regeneration. 
 
1.1 CORNEA 
The cornea is the transparent covering and the main refractive element of the eye. It is 
responsible for transmission of light to the retina. The human cornea is composed of 
three primary layers, an outermost epithelium layer, a middle stroma containing 
keratocytes and an innermost, single layer of endothelial cells[3]. Two acellular layers 
separate these cellular layers; Bowman’s layer that separates epithelium and stroma, 
and Descemet’s layer which separate stroma and the endothelium. There is an 
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additional, recently discovered, acellular layer termed as the pre-Descemet’s layer 
(Dua’s layer) that lies adjacent to the Descemet’s layer[4].  
The corneal epithelium is a stratified, non-keratinizing epithelium. Centrally, it is five 
cell layers thick, whereas, in the periphery, it is up to 10 cell layers thick. Cells of the 
epithelial layer are self-renewing, and their stem cells are located basally as will as in 
the limbus, which is a ring of tissue immediately adjacent part to the peripheral 
cornea[5].  
Keratocytes or stromal cells are neural crest-derived mesenchymal cells that make up 
approximately 3% of the total stromal volume[6].  The rest of the stroma comprises 
extracellular matrix (ECM) macromolecules consisting of mainly collagen and 
proteoglycans. Functional properties of the healthy cornea largely depend on the 
structure of corneal stroma, which is around 500um thick  (90% of the total cornea) and 
highly hydrated (78% water). Highly specific arrangement of collagen fibrils within the 
stroma is the reason behind corneal transparency[7]. Unlike corneal epithelial cells, 
stromal cells are not self-renewing and they remain quiescent throughout life. Upon 
injury to the stroma, keratocytes transform into mitotically active fibroblasts[8, 9], 
while ECM secreted by the fibroblasts[10] form a scar within the cornea that can lead to 
vision loss.  More recent studies have shown that stromal cells with stem cell specific 
markers have been isolated from the corneal limbal resign. These cells have the ability 
to differentiate into keratocytes and are most likely stem cells[11, 12].  
The corneal endothelium is a single layer of non-proliferative cells[13]. The density of 
the cells is 2-5x103 cells/mm2 in the normal human cornea[14]. The endothelium 
functions to maintain the hydration of cornea by pumping out excess water from the 
corneal stroma through their Na, K-ATPase pump[15]. In case of the loss of endothelial 
cells during the aging or wounding process, the exposed area becomes covered by 
increasing the overall cell size and altering the shape to fit the gap[16]. Recent studies 
showed that endothelial progenitor cells exist in the corneal periphery and have the 
potential to differentiate into functional corneal endothelial cells[17, 18].  
The cornea is the most densely innervated surface tissue of human body. Most of the 
corneal nerves are sensory in origin and originate from the ophthalmic branch of the 
trigeminal nerve. Corneal nerves lose their perineurium and myelin sheaths as they 
enter the vicinity of the limbus before entering into the cornea. They form a nerve 
  3 
plexus that lies parallel to the surface of the cornea[19]. Corneal nerves play an 
important role in sensory function, maintaining the homeostasis of the corneal 
epithelium, tear production and blinking[20]. The cornea does not have blood vessels. 
The nutritional requirement is fulfilled by the tears[21], aqueous humor[22] and also 
neurotrophins from its nerve supply. The highly hydrated and porous structure of the 
cornea allows for diffusion of solutes and nutrition throughout the structure[23]. The 
cornea is immunologically privileged[24] and is, therefore, a perfect model for studying 
transplantation and tissue engineering. 
 
1.2 CORNEAL DISEASES 
According to World Health Organization (WHO), 285 million people throughout the 
world are visually impaired, and among them, 39 million are blind[25]. One of the 
major causes of blindness worldwide is corneal disease, leading to loss of corneal 
transparency and deteriorating vision. There are a wide variety of infectious and 
inflammatory eye diseases that cause corneal scarring and may result in total blindness. 
Ulceration and trauma cause cornea related monocular blindness to 1.5–2.0 million new 
cases every year[26]. 
Microbial attack is a common cause of corneal disease. Endogenous antimicrobial 
peptides or proteins such as lysozyme, lactoferrin, phospholipase A2, defensins, and 
cathelicidins are present in the tear film. These provide host defense against microbial 
attack[27-31]. Alteration of this host defense mechanism makes the cornea susceptible 
to microbial attack.   
Herpes simplex virus (HSV) infection is one of the prime causes of corneal disease and 
loss of vision. HSV is a neurotrophic virus that infects the skin, mouth mucous 
membrane, genitalia and eyes. HSV serotype 1 (HSV-1) is commonly associated with 
corneal infections. Up to 500,000 cases per year of HSV infection in the cornea are 
reported in the USA alone. HSV-1 infection is the most frequent cause of corneal 
blindness in North America and reports of visual disability are as high as 40%[32]. The 
pathogenesis of the HSV-1 virus is complex. Initial exposure generally results in a 
primary infection during which the clinical signs can include the followings: 1) 
Infectious epithelial keratitis in which corneal epithelial ulcers (surface lesions) are 
  4 
present; 2) Neurotrophic keratopathy in which abnormal corneal innervation and poor 
tear production occur. The infection produces a non-healing surface ulcer that can 
progress into the deeper layers and cause corneal perforation; 3) Stromal keratitis that 
can be either necrotizing or non-necrotizing; and 4) Endothelialitis, which is an immune 
reaction at the level of the endothelium that may occur by months to years of HSV 
infection. After recovery from primary infection, the virus establishes latency in the 
trigeminal ganglion that supplies sensory neurons to the ocular surface[33] and also 
likely, within the cornea[34]. Prompts for reactivation are diverse and nonspecific 
including stress, immunosuppression and sunlight. The recurrent disease is generally 
more severe, involving the stroma as well as epithelium, leading to Herpes Simplex 
Keratitis (HSK). 
Bacterial and fungal keratitis are also common corneal diseases that can cause damage 
to the cornea and lead to blindness[35].  Most keratitis is associated with the use of 
contact lenses, e.g. infection caused by the bacterium, Pseuromonas aeruginosa[36] 
and the fungus, Fusarium solani[37]. Infective crystalline keratopathy is caused by 
Viridans streptococci[38], Staphylococcus epidermidis[39] and Candida albicans[40]. 
Trachoma, which is caused by the bacterium Chlamydia trachomatis, is related to 
corneal inflammation and scarring that affects 5 million people worldwide[26]. In most 
of the cases, bacteria form the biofilm, which makes them more resistant to 
conventional treatment[41].  
Keratoconus is another common and non-infectious-based corneal disease that is 
characterized by non-inflammatory and progressive thinning of the cornea. Genetic as 
well as environmental factors have been associated with this disease[42]. Keratoconus 
causes visual interference with multiple images and sensitivity to light[43].  
 
1.3 CORNEAL TRANSPLANTATIONS AND ISSUES 
The most widely accepted treatment for corneal blindness is transplantation of a full 
thickness healthy donor cornea after removal of the damaged tissue; a process termed as 
penetrating keratoplasty (PK)[44]. Unfortunately, the supply of donor tissue is 
substantially less than the demand for transplantation that has resulted in 10 million 
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untreated patients worldwide, with an additional 1.5 million new patients every 
year[26].  
Apart from the donor shortage, donor corneal grafting is contraindicated in a proportion 
of patients reasons such as autoimmune situations, chemical burns, and infections[45]. 
Graft failure due to the graft rejection remains the most challenging complication in 
corneal transplantation. The Swedish register transplantation database shows that the 2-
year rejection rate of transplanted donor corneas is quite low, at 15% with an overall 
complication rate of 26%[46].  The survival rate of corneal grafts, however, decreases 
over time to 62% at 10 years and 55% at 15 years[47].  
Although the healthy cornea is immune privileged, corneas that are inflamed and 
neovascularized are no longer immune privileged leading to graft rejection.  The loss of 
immune privilege is probably due to infiltration of blood vessels and lymphatics into 
the cornea. Rejection of a corneal graft is a CD4+ T cell-mediated response[48]. In the 
case of inflammation, host antigen-presenting cells (APC) are attracted into the stroma, 
and due to the local production of pro-inflammatory cytokines, major histocompatibility 
complex antigen gets overexpressed on grafted corneal cells. The up-regulation of alien 
histocompatibility complex triggers host immune system. This immune reaction against 
donor antigens results in rejection of corneal graft[49].   
Donor-cornea derived infection is another serious complication associated with 
transplantation of human donor corneas[50]. HSV-1 DNA isolated and characterized 
from donor corneas before and after corneal transplantation confirmed the transmission 
of HSV-1 through transplantation from donor to host[51]. Bacterial and fungal post-
keratoplasty endophthalmitis is another common complication that appears after five 
days of donor transplantation[52]. Processing and proper screening of donor corneas 
can reduce the complications of infection related to donor cornea transplantation. 
Screening is an expensive procedure, with processing fees in the USA around 2.5-3.5 
thousand US dollars per cornea[45]. Infection has been implicated in graft rejection. For 
example, corneal transplantation is the treatment of choice for HSV-induced corneal 
blindness[47] despite a poor prognosis (22% success at 5 years[53]) compared to 73% 
success at 5 years for non-HSV grafts[47]. After recovery from the primary infection of 
HSV, this virus may remain in the trigeminal ganglion as a latent state[54]. The virus 
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can reactivate after transplantation with a donor cornea and cause the same disease to 
the newly transplanted cornea[55].  
 
1.4 PROPOSED ALTERNATIVES TO HUMAN DONOR CORNEAS 
There has been a long history of research into the development of alternatives to human 
corneas, both artificial as well as natural alternatives.  
Xenografts have been tested since the 1800s. In 1838, Richard Sharp Kissam 
transplanted a cornea from a 6 months old pig into the cornea of a young Irishman, 
James Dunn, who suffered from a central leucoma. Within two weeks of 
transplantation, the cornea became opaque and was absorbed within one month[56]. 
During the same year, a sheep xenograft cornea was grafted into a human patient[57]. 
In this case, the grafted cornea became opaque. In all instances of xenografts, the 
implants failed due mainly to host immune reaction against the graft[58]. In addition, 
cross-species diseases are also a major complication of xenograft transplantation. To 
date, xenografts are still being tested. However, they are now treated to remove the 
cellular components to prevent immune rejection and screened to prevent pathogen 
transmission.   
Decellularized organs for potential transplantation have become popular in recent time 
due to their ability to retain the native ECM of the target organ[59]. Decellularized 
corneas have been studied to evaluate their potential as grafts in same or cross-
species[60]. There have been a number of methods developed to decellularize 
corneas[61, 62]. Most of the methods used 1) 0.1% sodium dodecyl sulfate (SDS)[63] 
for 7 hours, 2) hypoxic nitrogen (N2) for 7days[64] or 3) hypertonic NaCl for 48 
hours[65]. The human cornea was decellularized and evaluated for the reconstruction of 
corneal epithelium and stroma, in vitro[61]. In 2015, decellularized porcine corneas 
have been successfully transplanted into patients in clinical evaluation. Forty-seven 
patients with the fungal corneal infection were transplanted with the decellularized 
porcine cornea. Up to 6 months of post operation, there was no recurrence of infection 
and corneas became re-epithelialized. Visual improvement was reported for 72% of the 
patients although neovascularization was reported in 53% of the patients[66].  
Decellularized tilapia fish scale-derived extracellular matrix has also been tried in a rat 
  7 
model to evaluate the biocompatibility. The short term (21days) result ended up with 
the haziness, neovascularization around the sutures, obscuring the pupil, melting of the 
anterior corneal lamella and local swelling; depending on the place in the cornea the 
scale was transplanted[67]. But in traumatic perforations in a mini-pig model, fish scale 
cornea showed promising results in a very short-term study (3-4 days) with only mild to 
moderate swelling in the perforated cornea[68].     
Stem cell treatment, in contrast to decellularized corneas, is another commonly 
accepted therapy, particularly with problems related to deficiency of the stem cells of 
the corneal epithelium, i.e. limbal stem cell deficiency[69]. Limbal stem cell deficiency 
is overcome by grafting small pieces of the health eye’s limbus to the damaged eye[70]. 
More recently, limbal stem cells have been cultured in vitro to expand their numbers 
and then grafted into cell deficient eye[71]. Autologous grafts obtained from the healthy 
contralateral corneas have worked very well[72]. Burn related destruction of the lumbus 
resulting in limbal stem cell deficiency has been successfully treated with autologous 
cultured limbal stem cells from contralateral eye[72] cultured on human amniotic 
membranes[73] or fibrin substrates[74]. Within our group, we have shown that a 
stratified epithelium layer can be reconstructed by seeding limbal cells on top of 
collagen-based materials[75]. The expansion of stem cells requires the use of certified 
cleanrooms following Good Manufacturing Practice (GMP) guidelines. This therefore 
limits the ability to perform stem cell transplantations to large, affluent tertiary 
healthcare centers. Recently, however, a technique known as Simple Limbal Epithelial 
Transplantation (SLET) was developed to allow for transplantation of stem cells 
without the need for expansion of stem cells. In this technique, a healthy limbal 
(2x2mm) part is divided into small pieces and expanded in vivo in the stem cell-
deficient eye with the help of amniotic membrane and fibrin glue[76]. Two-amniotic 
membranes are also used to sandwich harvested limbal stem cell to protect the cells 
from hostile microenvironment[77]. Multicenter clinical trial with autologous SLET 
technique showed the 83.8% success rate with the complete epithelization and 
avascular corneal surface within 6 months post-operation[78].    
Artificial corneas known as keratoprostheses (KPro’s) have been in development for 
over 200 years. In 1789, French scientist, Pellier de Quengsy proposed replacement of 
opaque corneas using a glass alternative[79]. In 1855, a quartz crystal implant was first 
transplanted into a human[80]. In the second half of the 20th century, core-and-skirt 
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designs for artificial corneas became common. This design comprised of a transparent 
plastic optical core (e.g. poly (methyl methacrylate)) and a porous skirt of different 
materials. The most successful among this approach is the Boston KPro. In this KPro, a 
donor cornea is positioned between the front and back plates[81]. Boston KPros’ are 
well retained. Development of glaucoma, retroprosthetic membrane formation, and 
persistent epithelial defects, however, remain as postoperative difficulties 
encountered[82, 83]. Other problems include the need for lifetime antibiotics, and in a 
proportion of patients, immune suppression is required.  
The AlphaCor is another well-known KPro that used in the clinic[84]. In this KPro, 
both optic and skirt are made from poly (2-hydroxyethyl methacrylate) (PHEMA). The 
optic is solid, but the skirt contains interconnecting pores that allow biointegration with 
adjacent corneal tissue. The retention rates of AlphaCor after 1, 2 and 3 years of 
transplantation were 87%, 58%, and 42%, respectively. Due to the low water content of 
PHEMA based AlphaCor, the KPro has reduced permeability to glucose and other 
solutes, which may account for the decreasing implant survival over time. In order to 
increase the water content of PHEMA-containing implants, methacrylic acid monomers 
were incorporated into the PHEMA. The surface of this KPro was treated with laminin 
and fibronectin, which increased corneal epithelial growth in vitro[85, 86]. In another 
approach, KPro was designed to selectively assist different corneal cells growth. In this 
approach optic core was made of a dual network of poly (ethylene glycol) and poly 
(acrylic acid) (PEG/PAA) to support epithelization and skirt is made of microperforated 
poly(hydroxyethyl acrylate) (PHEA) that encourages stromal tissue integration[87]. In 
vivo biocompatibility of PEG/PAA based materials were tested in rabbit cornea[88].  
The osteo-odonto-keratoprosthesis or OOKP is another type of KPro that contains 
dental tissue enveloped with autologous oral mucosal cells[80, 89]. OOKP implantation 
requires a two-stage surgical procedure. The first stage involves the harvesting of a 
monoradicular tooth to prepare osteo-odonto-lamina. A hole is drilled through dentine, 
and poly(methyl methacrylate) (PMMA) optic cylinder is placed into the hole. This 
implant then placed into a submuscular pouch within the oral mucosa for 2-4 months. 
By this time, the OOKP becomes vascularized to maintain a blood supply. During the 
second stage, the graft is removed and placed in the eye after removing the cornea up to 
Bowman’s layer. OOKP implantation is a complicated procedure, but the survival rates 
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are high as it can withstand hostile ocular environment and in a severely dry eye 
condition[90]. 
 
1.5 HUMAN RECOMBINANT COLLAGEN BASED ARTIFICIAL 
CORNEAS 
As collagen is the main competent of the corneal extracellular matrix, artificial corneas 
made from collagen have garnered a lot of interest as alternatives to human donor 
corneas. The main source of collagen is extracted animal protein, although 
recombinantly produced collagen is now available. To give mechanical strength and 
feasibility for transplantation, collagen is cross-linked by different mechanisms[91-94]. 
The most conventional crosslinking method is using with N-(3-dimethylaminopropyl)-
N'-ethylcarbodiimide (EDC) and N-hydroxysuccinimide (NHS)[95]. The EDC cross-
linking reaction starts with the activation of the carboxylic acid groups of Asp or Glu 
residues of collagen by EDC. The reaction of the carboxylic acid with EDC gives O-
acylisourea, an intermediate reactive group. O-acylisourea is very unstable to 
hydrolysis. NHS converts the O-acylisourea group into a NHS-activated carboxylic 
acid group. The resultant then reacts with amine groups of lysine and the final product 
will be zero length cross-linked collagen[96].  Optically transparent and cell friendly 
corneal implants were made from porcine and bovine collagen and transplanted into 
animal models[97, 98]. However, porcine collagen-based corneas when grafted in mice 
showed immunogenic reaction[99]. Animal-derived collagen comes from 
heterogeneous sources, and because of the different levels of processing and screening 
in each different source, great care needs to be taken due to the risk of transmitting 
diseases[100] as well as provoking immune responses in the host[101].  
The use of recombinant human collagen mitigates the heterogeneity and pathogen 
transmission issue. Recombinant human collagen production has been developed using 
mammalian cell culture systems[102], insect cell cultures[103], silkworm[104], tobacco 
plants[105] and yeast[106, 107].  Only mammalian cells expressed full-length 
hydroxylated collagen. All other expression systems are lack proline hydroxylation 
result in the production resulting in an unstable collagen that is readily degraded by 
proteolytic degradation[108].  In the yeast, Pichia pastoris, co-expression of prolyl 4-
hydroxylases with the collagen gene facilitates the production of stable collagen in a 
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recombinant manner[107, 109]. P. pastoris has been used to express type I, II and III 
collagen[110]. Recombinant human collagen-based artificial corneas have been made 
from both type I and III collagen. Both types of collagen showed similar mechanical 
properties and in-vivo biocompatibility in mini-pigs although type III implants were 
superior in optical clarity[111]. Type III recombinant human collagen (RHC) based 
artificial corneas have been tested in a Phase I clinical trial on 10 patients in Sweden. 
RHC was crosslinked with EDC/NHS and fabricated into implants. They were grafted 
into 10 patients. Nine patients had keratoconus while the tenth had a central corneal 
scar[44].  The implants promoted regeneration of corneal epithelium, stroma, and 
nerves from the patients’ endogenous cells. The grafted corneal implants have remained 
stable for four years without any rejection and without sustained immune suppression. 
At the 4-year follow-up (Fig. 1), the implanted cornea remained stably integrated into 
the host eye[112]. In vivo confocal microscopy showed that corneal cells had populated 
the implant (Fig. 2).  
 
Figure 1. Slit lamp biomicroscopy images of the corneas of all 10 patients transplanted with recombinant 
human collagen implants at 4 years post-operation (From Biomaterials. 2014 Mar;35(8):2420-7). 
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Figure 2. Typical in vivo confocal microscopic appearance of four-year post-operation, unoperated and 
normal corneas. (From Biomaterials. 2014 Mar;35(8):2420-7)  
One patient had undergone re-grafting as he could not be properly fitted with contact 
lenses for visual acuity. Histopathology of the neo-cornea obtained showed that it had a 
normal corneal structure, although a part of corneal implant still remained[113].  
To improve the functionality and increase resistance to enzymatic degradation in the 
severe disease condition, a new artificial cornea was developed using interpenetrating 
polymer networks (IPN) of collagen and phosphorylcholine. These implants were tested 
in mini-pig, guinea pig and rabbit models[114-116]. In that case 2-
methacryloyloxyethyl phosphorylcholine (MPC) was polymerized with poly(ethylene 
glycol) diacrylate (PEGDA) with the help of ammonium persulphate (APS) and 
N,N,N,N tetramethylethylenediamine (TEMED)[116].   
 
1.6 ARTIFICIAL CORNEAS BASED ON PEPTIDE ANALOGS OF 
COLLAGEN 
About 90% of the world’s visually impaired live in low-income nations[25]. Production 
and purification of RHC in yeast is an expensive process that makes the price of the 
artificial cornea unreachable to the most needy individuals. Therefore, an alternative 
that could replace RHC with the same physicochemical and biological properties would 
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be a huge advancement. Collagen-like peptides (CLP) or collagen mimetic peptides 
have been developed as functional alternatives of collagen [117].  
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2 AIMS OF THIS PROJECT 
Artificial corneas have been developed as an alternative to donor human corneas and 
recently, our group has shown that implants based on recombinant human collagen 
have successfully promoted regeneration of corneal tissues and nerves in a small 
clinical trial. However, these implants are not amenable to grafting in patients with 
severe pathologies. We hypothesize that the structural integrity and mechanical 
properties can be enhanced in several ways, ranging from incremental changes by 
incorporation of a second network of materials, peptides to surface modification and 
surgical handling techniques. We also hypothesize that the functional properties of full-
length collagen can be replicated using shorter peptide analogs to collagen.   
The specific aims of this thesis were therefore to: 
• characterize the ultrastructural properties of collagen versus collagen-MPC 
cornea implants to understand how they can be improved 
• optimize the collagen-MPC formulation by enhancing the mechanical and 
chemical properties by examining the effects of a new epoxy-based crosslinker, 
and incorporation of laminin-derived cell adhesion peptides, YIGSR and 
IKVAV 
• optimize the functionality of collagen-MPC implants by surface modification 
using microcontact printing, and evaluating its performance as an implant by 
examining the effects of laser-cutting  in potential surgical use 
• evaluate a collagen-like peptide hydrogel as an analog to collagen-based 
hydrogels in vitro and in vivo 
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3 MATERIALS AND METHODS 
Please refer to Papers I-V for the detail description of the materials and methods used in 
this thesis.  
3.1 ETHICAL CONSIDERATIONS 
Paper IV 
Dr. Lucia Kuffova, University of Aberdeen, UK, performed the animal studies, had a 
permit from the Ophthalmic Research and Animal License Act (United Kingdom). 
Project license number was 60/3890. 
Paper V 
After ethical approval from the local ethical committee, Linköpings Djurförsöksetiska 
Nämnd (Dnr 52-15), and in compliance with the Swedish Animal Welfare Ordinance 
and the Animal Welfare Act, materials were implanted in the rats subcutaneously. 
After permission from Stockholms Norra Djurförsöksetiska Nämnd (N204/13), 
materials were transplanted into pig corneas.  
 
3.2 RHC-MPC ARTIFICIAL CORNEAL IMPLANT  
RHC used in for the papers was purchased from FibroGen Inc. (San Francisco, USA) 
and 3H Biomedical (Uppsala, Sweden). For making hydrogels, approximately 500 mg 
of RHC solution was buffered with 150µl of 0.625M 2-morpholinoethane sulfonic acid 
monohydrate (MES) buffer. MPC solution in MES was added into a syringe mixing 
system (Fig. 3) for through mixing.  
 
    Figure 3. Syringe mixing system             Figure 4. Jigs with 500 µm moulds 
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The MPC:RHC (w/w) ratio used was 1:2. PEGDA was then added (PEGDA:MPC 
(w/w) = 1:3). Calculated volumes of 4% (w/v) APS solution in MES and 2% (v/v) 
TEMED solution in MES were added sequentially (APS:MPC (w/w) = 0.03:1, 
APS:TEMED (w/w) 1:0.77). Calculated amounts of NHS (10% (w/v) in MES) and 
EDC (5% (w/v) in MES) solutions were added and the reactants were thoroughly mixed 
at 0oC (EDC:RHC-NH2 (mol:mol) = 0.4:1, EDC:NHS (mol:mol) = 1:1). The final 
mixed solution was immediately cast into cornea-shaped moulds (12 mm diameter, 500 
µm thick) (Fig. 4).  
In paper II, RHC-MPC hydrogels were made with slight modifications. Different 
RHC:MPC (w/w) ratios were used as 1:1, 2:1 and 4:1. EDC:RHC-NH2 (mol:mol) ratios 
were 0.3-1.5:1. APS:MPC (w/w) ratio was 0.015:1. For microcontact printing, 
RHC:MPC (w/w) ratio of 1:2 with EDC:RHC-NH2 of 0.4:1 was used.  
 
3.3 EPOXY-CROSSLINKED COLLAGEN HYDROGELS WITH 
INCORPORATED LAMININ PEPTIDES 
1,4-Butanediol diglycidyl ether (BDDGE), a bi-functional epoxy crosslinker, was used 
to crosslink an aqueous solution of type 1 porcine collagen (10% w/v) with the 
intention of enhancing the mechanical properties of the hydrogel by increasing its 
elasticity (Paper III). BDDGE was used alone to crosslink at basic pH and in the 
combination of EDC/NHS at acidic pH. The same syringe mixing system as above was 
used to thoroughly mix up the hydrogel components with sodium bicarbonate buffer for 
hydrogels made under basic pH conditions, and MES for the acidic conditions. For 
hydrogels prepared under the basic conditions, 1 molar equivalent (relative to the 
collagen lysine residues) of BDDGE was used. For acidic conditions, 0.4 molar 
equivalents of BDDGE were used together with 0.5 molar equivalent of EDC/NHS. 
The final products of both formulations were then cast into moulds and cured within a 
humidified chamber for 24 and 72 hours for the basic and the acidic conditions, 
respectively. Under the acidic condition, 0.3 molar equivalent Cu+ was used to catalyze 
the formation of the amide bonds with epoxides. YIGSR and IKVAV, small cell 
adhesive peptides derived from laminin were incorporated into the acidic hydrogel at 
0.001 molar equivalent concentrations to collagen amine, to increase cellular 
biocompatibility properties of the hydrogel.    
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3.4 SYNTHESIS OF COLLAGEN-LIKE PEPTIDE (CLP) AND 
FABRICATION OF HYDROGEL 
3.4.1 Synthesis of CLP-PEG 
A 38 amino acid long CLP peptide, CG- (Pro-Lys-Gly)4(Pro-Hyp-Gly)4(Asp-Hyp-
Gly)4, was synthesized using a Symphony automated peptide synthesizer (Protein 
Technologies Inc., Tucson, AZ, U.S.A.) using standard fluorenylmethoxycarbonyl 
(Fmoc) chemistry. The resulting peptides were split from the resin by treatment with a 
mixture of trifluoroacetic acid (TFA), water and triisopropylsilane (TIS) (95:2.5:2.5 
v/v; 10 mL per gram of polymer) for 2h at ambient temperature. The CLP was then 
precipitated by the addition of cold diethyl ether, followed by centrifugation and 
lyophilization. Purification was done using reversed-phase High Performance Liquid 
Chromatography (HPLC) on a semi-preparative C-18 column (Grace Vydac, 
Helsingborg, Sweden). 
The solution of CLP and 8-Arm PEG-Maleimide was mixed at the molar ratio of PEG-
Maleimide:CLP=1:5. After 4 days of continuous stirring the mixture was dialyzed 
through a dialysis membrane (12-14,000 molecular weight, Spectrum Laboratories, 
Inc., CA, US). After dialysis, the solution was lyophilized to obtain solid CLP-PEG.  
3.4.2 Fabrication of hydrogel 
To fabricate corneal implants, 500mg of 12% (w/w) CLP-PEG was taken into a 2ml 
glass syringe. Calculated volumes of NHS and then EDC were added to the syringe 
mixing system we used previously. Depending on the molar equivalent ratio of EDC to 
the amine of CLP-PEG, three different types of hydrogels were made; CLP-PEG-NH2: 
EDC=1:0.5, CLP-PEG-NH2: EDC=1:1 and CLP-PEG -NH2: EDC=1:2. The molar ratio 
of EDC: NHS was 1:1. As a negative control of in-vitro biocompatibility, hydrogels 
were made by 8-Arm PEG-Maleimide and 8-Arm PEG-Thiol together at a molar ratio 
1:1 at 37oC. CLP-PEG-NH2: EDC=1:2 was used for further characterizations and 
animal studies.    
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3.5 CHARACTERIZATION 
Structural and optical properties of the RHC-MPC corneal implants were examined in 
Paper I, using transmission electron microscopy (TEM), X-ray scattering, spectroscopy, 
and refractometry.   
Light transmission, refractive index and water content of the implants were measured. 
Thermal stability of the materials was measured by differential scanning calorimeter 
(DSC, Q20, TA Instruments, New Castle, UK). Tensile strength, elongation at break 
and elastic modulus was measured (not as a part of the Quality control for clinical use) 
by Instron machine (Biopuls, High Wycombe, UK). Fourier transform infrared 
spectroscopy (FTIR, VERTEX 70, Bruker, Billerica, MA, USA) confirmed the 
presence of different functional groups present on the surface of the materials.  
The feasibility of using femtosecond laser assisted cutting for RHC-MPC hydrogels 
was tested, to determine whether the hydrogels were amenable to the laser-assisted 
surgical grafting of corneal hydrogel implants.  
To confirm the conjugation of CLP with PEG-Maleimide, 1H NMR spectra was 
measured using an Oxford 300 MHz (Varian, CA, US) spectrometer at room 
temperature. CLP was dissolved in D2O (1mg/0.1ml) whereas CLP-PEG and 8-Arm 
PEG-Maleimide was dissolved in C2D6OS (1mg/0.1ml) (Paper V).  
Triple helicity of CLP-PEG was confirmed using circular dichroism (CD) on a 
Chirascan CD Spectrometer (Applied Photophysics Ltd, Surrey, UK). CLP-PEG was 
dissolved in water at a concentration 0.5% (w/v). The solution was scanned at a range 
of wavelengths from 180 to 260nm at 25oC, and its ellipticity, θ (mdeg) was recorded 
(Paper V). 
 
3.6 COLLAGENASE STUDY 
Enzymatic degradation of hydrogels was performed using collagenase from 
Clostridium histolyticum (Sigma-Aldrich). Small pieces of hydrogels were placed in 
5U/ml collagenase solution in 0.1M tris-HCL (pH 7.4) containing 5mM CaCl2. The 
hydrogels were incubated at 37oC and the collagenase solution was changed at every 8 
hours. The gels were weighed at specific time pauses after removal of surface water. 
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The enduring mass of the hydrogels was traced as a function of time, comparative to 
their original hydrated weight. 
Residual mass % = Wt / Wo % 
Wt is the weight of hydrogel at a certain time point, and Wo is the initial weight of the 
hydrogel. 
 
3.7 CELL CULTURE 
Human corneal epithelial cells (HCEC) and GFP-HCEC (green fluorescence protein-
tagged Human corneal epithelial cells) were used to evaluate the proliferation of cells 
on the hydrogels. Cells were maintained in KSFM supplemented with epidermal 
growth factor (EGF) and bovine pituitary extract (BPE) at 37oC incubator. Images of 
cultured cells were taken at different time point by using fluorescence microscope 
(AxioVert A1, Carl Zeiss, Göttingen, Germany). Tissue culture plate (TCP) was used as 
a positive control for culturing HCEC.  
In Paper III, HCEC was seeded on different hydrogel and MTS was done to examine 
the proliferation of the cells. To evaluate the effect of incorporation of laminin peptides, 
HCECs and rodent hybrid dorsal root ganglia- neuroblastoma cells (NDC)[118] cells 
were seeded on peptides containing hydrogels and proliferation was measured over 
time.  
 
3.8 IMMUNOHISTOCHEMISTRY 
For immunohistochemistry (Paper II) HCECs were cultured on hydrogels for four days. 
Then cells were fixed, permeabilization and block. Cells were incubated with anti-
proliferating cell protein Ki67 antibody (Sigma–Aldrich, MO, USA), anti-focal 
adhesion kinase (FAK) antibody (Abcam, Cambridge, UK) and anti-integrin beta 1 
(integrin β1) antibody (Abcam, Cambridge, UK) followed by incubation with 
secondary antibody, Alexa Fluor-594 (Invitrogen, Oregon, USA). A confocal 
microscope (LSM700, Carl Zeiss, Göttingen, Germany) was used to visualize and 
capture the images.  
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3.9 IN VIVO BIODEGRADATION 
All materials of 10mm diameter and 500um thick were implanted subcutaneously into 
three Albino Wistar rats (Charles River, USA) after anesthetized with Isoflurane (5% 
for induction and 2% for maintenance). The subchronic effect of the implants and 
overall biodegradation was evaluated according to the ISO 10993-6 (International 
organization of standardization, Tests for local effects after implantation, Biological 
evaluation of medical devices, Geneva, Switzerland) guideline. For implantation, two 
small incisions were made paravertebrally on the backs of the each rat. Implants were 
inserted, and the wound was closed with 2-3 interrupted sutures. After 90 days, the 
animals were euthanized, and the implanted materials were removed from the host 
together with surrounding tissue for histopathological analyses. 
 
3.10 IN VIVO IMPLANTATION OF CORNEAL CONSTRUCTS IN ANIMAL 
CORNEAS  
With a license from Home Office, UK, RHC-MPC implants were tested for their ability 
to tolerate the adverse environment within mice with HSK corneas. Mice were infected 
with HSV-1 viruses at six weeks before implantation and had developed HSK.  1.5mm 
diameter of hydrogels was grafted into corneas that had HSK and retained using 
continuous sutures.   
RHC-MPC corneal implants were also tested in corneas of mini-pigs. With ethical 
approval (N204/13) from the regional animal experimental ethics committee in 
Stockholm (North), RHC-MPC & CLP cornea shape materials (500µm thick and 
6.5mm diameter) were transplanted into the cornea of Göttingen mini-pigs (Ellegaard, 
Denmark). A Swedish Medical Products Agency contract research laboratory, Adlego 
Biomedical AB, 75103 Uppsala, Sweden, conducted the entire experiment (Study plan: 
AB13-32). Two groups of four female mini-pigs in each group, aged 5-6 months at the 
beginning of the procedure were grafted with corneal implants comprising RHC-MPC 
crosslinked with EDC/NHS and CLP-PEG. Prior to the surgery, animals were 
anesthetized with isoflurane (0.5-3%, IsoFlo vet, Abbott Laboratories, UK) in oxygen 
and air. Tetracain 1% eye drop (Chauvin Pharmaceuticals Ltd, UK) was applied on 
ocular surface as topical anesthesia. Each pig cornea was cut circularly with a trephine 
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to a depth of 500um and 6.50mm diameter, and the corneal bottom was manually 
dissected and removed. Then implant material was cut with a 6.75mm diameter 
trephine and placed on the surgically removed corneal wound bed, as in deep lamellar 
keratoplasty (DLKP). All implants were covered with the human amniotic membrane 
(HAM) (St:Erik’s Eye Hospital, Stockholm) and the implants were kept in place using 
overlying sutures. Upon completion of the surgery, antibacterial and anti-inflammatory 
ophthalmic suspensions (3mg/ml dexamethasone and 1mg/ml tobramycine, Alcon, 
Sweden) were administered. The maintenance dose was 1 drop, 3 times daily for 5 
weeks.  The unoperated eye of each pig served as a control.  
The mini-pigs were examined at 3, 6, 9 and 12 months post-operation. Clinical 
examinations conducted at these times included slit lamp biomicroscopy (using a Kowa 
SL-15 Portable Slit Lamp, Kowa company, Ltd., Aichi, Japan), Schirmer’s tear test, 
intraocular pressure (IOP; measured using a Tonovet Tonometer, Icare Finland Oy, 
Finland), corneal touch sensitivity using aesthesiometry (measured using a Cochet-
Bonnet aesthesiometer, Handaya Co., Tokyo, Japan), corneal thickness measurement by 
Handy Pachymeter SP-100 (Tomey, AZ, USA), and in vivo confocal microscopy 
(IVCM; using a Heidelberg HRT3 Rostock Cornea Module, Heidelberg Engineering 
GmbH, Dossenheim, Germany). The McDonald-Shadduck scoring system was used to 
score results of the slit lamp evaluation[119]. IVCM images were used to analyze 
different cell types, tissue structure, and density of nerve[120].  
At 12 months post-operation, the animals were euthanized with an overdose of 
pentobarbital (Allfatal vet 100mg/ml, Omnidea, Sweden). Both operated and control 
unoperated corneas were harvested for further evaluation.  
 
3.11 BIOCHEMICAL ANALYSIS ON EXCISED PIG CORNEAS  
Biopsies (3 mm) from within the operated area and from unoperated control corneas 
were collected for biochemical analyses.  Samples were suspended in 10 mM HCl.  
Pepsin (Sigma Aldrich, USA) was added to a final concentration of 1 mg/mL from a 10 
mg/mL stock solution prepared just before use.  The samples were digested with pepsin 
at 2-8°C for 96 hours, and the soluble fraction was recovered by centrifugation. An 
aliquot of the pepsin soluble fraction was mixed with NuPAGE 4X LDS sample buffer 
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(Life Technologies), denatured at 75°C for 8 minutes and analyzed on a 3 - 8% Tris-
acetate gels under non-reducing conditions or 4 -12% Bis-Tris gels (Life Technologies) 
under reducing conditions.  Proteins were visualized by staining with Gelcode Blue.  
Precision Plus Markers and porcine skin type I collagen were used as molecular weight 
standards.  To determine whether there were quantitative differences in the amounts of 
type I and type V collagens in operated and unoperated corneas, densitometric scans of 
the stained gels were made to obtain relative numerical units using a GE Healthcare 
Image Quant 350.  ANOVA or pairwise t-tests were performed to determine statistical 
differences using GraphPad Prism 5.  
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4 SUMMARY OF THE RESULTS 
4.1 CHARACTERIZATION OF RHC-MPC IMPLANTS  
4.1.1 Physical and mechanical characterization 
RHC-MPC hydrogels had a refractive index of 1.334, which is very similar to the 
hydrated human cornea and identical to that of water. These hydrogels transmitted 92% 
of incident light with 500nm wavelength spectra. Wide-angle X-ray scattering showed 
the uniaxial orientation of collagen throughout RHC-MPC.      
Formulations with a 2:1 ratio of RHC:MPC were optimal for fabrication of implants. 
Changes in MPC content did not change the properties of the hydrogels mechanically. 
Increased collagen content increased the tensile strength of the RHC-MPC hydrogels 
but resulted in overall stiffer and less elastic constructs.   
The thermal degradation temperature of RHC-MPC hydrogels was lower than human 
cornea but far above than usual body temperature. FTIR analysis confirmed the IPN 
formation showing the peaks for both collagen and MPC of the surface of the implants, 
which resemble by the increased stability against collagenase degradation.  
4.1.3 In vivo compatibility 
RHC-MPC implants were transplanted in herpetic mice model (Paper IV) and the 
results showed that implants remain in the host for 22 days whereas allograft got 
rejection by day 15-post operation. 
In paper V, the subcutaneous study in rat showed that the RHC-MPC materials did not 
trigger the immune reaction against the materials. Implantation into pig corneas showed 
stable integration with infiltration of corneal cells in the materials. Biochemical analysis 
of excised cornea confirmed the presence of α1 and α2 of collagen type 1; and α1 of 
collagen type V. 
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4.2 SURFACE MODIFICATION OF RHC-MPC IMPLANTS  
The microcontact printing had only a minor effect on the optical properties of the 
hydrogels. The percentage of transmitted light measured for implants with 30µm stripes 
was 99% with a backscatter of 1.7%; while the 200µm striped samples showed light 
transmission of 96% and backscatter of 0.6%. Atomic force microscopy (AFM) 
analysis showed that the printed areas did not affect the overall surface properties of the 
implants. The height difference between patterned and unpatterned areas was 
negligible. 
Analysis of the patterns showed that the highest number of cells was found on the 
200µm patterned strips. However, immunohistochemical analysis showed the highest 
expression of integrin β1, FAK, and Ki67 at 30µm patterned stripes. 
 
4.3 EPOXY CROSS-LINKED COLLAGEN HYDROGELS  
4.3.1 Physical and mechanical characterization 
BDDGE crosslinking under basic conditions allowed the formation of collagen 
hydrogels. Under acidic conditions, both BDDGE and EDC/NHS were needed for 
gelation. The optical and thermal properties were similar for both BDDGE and 
EDC/NHS crosslinked hydrogels, but the denaturation temperature increased for 
BDDGE hydrogels compare to EDC/NHS crosslinked control hydrogels. The 
mechanical properties differed between the acidic, and basic BDDGE crosslinked 
hydrogel. Hydrogels made under of acidic conditions showed 147% elongation at break 
while that made under basic conditions showed 14.02% elongation. Results from 
femtosecond laser assisted cuts revealed that BDDGE crosslinked hydrogel could cut 
precisely using the laser.  
4.3.2  In vitro biocompatibility 
Cell proliferation was decreased in BDDGE crosslinked hydrogels. However, upon 
adding laminin peptides, YIGSR increased proliferation of HCEC while IKVAV 
increased NDC proliferation.    
  24 
4.4 CLP-PEG HYDROGELS  
4.4.1 Physical and mechanical characterization 
1H NMR spectra of 8-Arm PEG-Maleimide and CLP-PEG confirmed the conjugation 
of CLP with PEG-Maleimide. Peaks at 6.5-6.6 at PEG-Maleimide spectra attributed to 
the proton attached to the -C=C- group of Maleimide on PEG. CD of CLP-PEG showed 
the triple helix characteristic with a positive peak at 221nm at 25oC. CLP-PEG was 
possible to crosslink with EDC/NHS and formed the stable hydrogel that holds the 
structure of the artificial cornea. CLP-PEG hydrogels were >90% transparent and water 
content was also over 90%. CLP-PEG hydrogels were completely resistance to 
collagenase degradation at high concentration of EDC.  
4.4.2  In vitro biocompatibility 
In vitro biocompatibility of the hydrogels was tested against HCEC and result showed 
that no cytotoxicity of the materials with the confluence of cells within 5 days at the 
initial of 5000 cells on 96 well place.  
4.4.3 In vivo compatibility 
Results from the subcutaneous study revealed that, up to 12 weeks of transplantation, 
CLP-PEG showed complete biocompatibility without inflammation and fibrosis. 
Artificial corner made from CLP-PEG implanted in mini-pig and examined over 12 
months at GLP facilities. In-vivo confocal microscopy showed corneal cells growth in 
the materials including subepithelial nerve. Biochemical analysis on the excised corneas 
showed the presence of type I and V collagens in quantities resembling those of the 
untreated control corneas as well as RHC-MPC benchmarks.  
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5 DISCUSSION  
5.1 PHYSICAL AND MECHANICAL PROPERTIES 
Optical characterization performed in Paper I was crucial for using RHC-MPC as a 
corneal implant, and the results showed the implants were as transparent or more 
transparent than human corneas. The reasons for being transparent are high water 
content, narrow aligned collagen fibers and a uniform refractive index. Being cell-free, 
RHC-MPC implants were also found to be transparent to UV light that is unlike to 
normal human cornea, which is populated by cells. In particular, the corneal epithelium 
absorbs UV light and thereby protects the inner components of the eye against 
potentially harmful UV rays. These results suggest that patients transplanted with RHC-
MPC implants should use UV protection during the early stages of regeneration until 
they become populated by in-growing endogenous host cells.  In Paper II, SEM results 
suggested that RHC-MPC hydrogels had a lamellar organization of collagen fibrils with 
interpenetrating networks that were more closely mimics the microstructure of the 
native cornea than RHC alone. 
5.1.1 In vivo biocompatibility in animal models 
Previously, it was shown that incorporation of MPC into RHC hydrogels allowed the 
implants to withstand in-growth of neovascularization in rabbit models of alkali 
burns[115]. More recent reports show that MPC has anti-inflammatory properties[121, 
122]. Incorporation of MPC into the RHC implant also enhanced the mechanical 
properties of the implants. Although the stability of RHC-MPC implants was increased 
in case of enzymatic degradation, the overall strength of the implant remains far weaker 
than native cornea[123]. The lower mechanical strength could be accounted for by the 
absence of proteoglycans, the absence of Bowman’s membrane, the small diameter of 
aligned uniaxial collagen fibrils and the overall low concentration of collagen within the 
hydrogel.  
When transplanted into HSV mice (Paper IV), RHC-MPC implants survived 7 days 
longer than allograft although this difference was not significant due mainly to the 
small sample size. However, this result indicates implants were at least comparable to 
allograft to stand against the hostile environment in HSV cornea.   
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In Paper V, implantation of the RHC-MPC hydrogels into rats confirmed that the 
implants were fully biocompatible. When implanted into the corneas of mini-pigs, there 
were fine blood vessels found in early post-operation condition but these retreated by 6 
months post-operation. By 12 months post-operation, the initially cell-free corneal 
implants became populated by epithelial and stromal cells. They were also reinnervated. 
 
5.2 MICROCONTACT PRINTING ON RHC-MPC HYDROGELS  
Microcontact printing (µCP) has been used to integrate biologically active 
macromolecules onto the surfaces of solid substrates without the loss of their 
activity[124, 125]. Microcontact printing has been mainly described as patterning on 
hard surfaces such as glass, silicone (e.g. polydimethylsiloxane (PDMS)) and silicon 
oxide, polystyrene, PMMA (polymethylmethacrylate) and gold[124-126]. In Paper II, 
we achieved reproducible µCP on thick, highly hydrated RHC-MPC hydrogels, using 
fibronectin, as “ink”. Fibronectin is a large glycoprotein present in the basement 
membranes of the corneal epithelium[127]. Cell attachment to fibronectin has been 
shown to trigger β1 integrin-FAK signaling to initiate proliferation of metastatic lung 
cancer cells [128] and in our case, HCECs. Expression of β1 integrin, FAK and Ki67 
was upregulated in cells growing on 30 µm stripes over broader 200 µm stripes or 
unpatterned surfaces. This showed that the width of the patterned fibronectin stripes 
was able to influence cell behavior.   
 
5.3 BDDGE CROSSLINKED HYDROGELS 
Epoxy-containing crosslinkers such as BDDGE have been shown to crosslink collagen 
producing hydrogels. In this thesis, crosslinking porcine type 1 collagen with BDDGE 
resulted in hydrogels with enhanced elastic properties. BDDGE can crosslink at acidic 
pH in the presence of a catalyst as mentioned in other published report; Cu (Copper) 
catalyzes the formation of secondary amine bond when epoxide reacts with amine[129]. 
BDDGE was used to crosslink collagen at acidic condition together with a secondary 
crosslinker, EDC/NHS. As an alternative approach, BDDGE was used to crosslink 
collagen at basic pH as isoelectric point of collagen lysine is basic, which facilitates the 
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crosslinking reaction through amine and epoxide[129, 130]. IKVAV and YIGSR, 
laminin peptides were incorporated into the hydrogel in acidic condition to enhance the 
cell attachment and proliferation, as they improve the cellular response of the 
biomaterials[131]. IKVAV showed increased neuronal cell viability and 
differentiation[132]; and YIGSR showed improved cell attachment[133] together with 
enhance collagen synthesis in human dermal fibroblasts[134]. In our case, like other 
published reports, IKVAV and YIGSR enhanced NDC and HCEC proliferation, 
respectively.  
 
5.4 CLP-PEG HYDROGELS 
O’Leary and co-workers (2011) described a 36 amino acid peptide, Pro-Lys-Gly)4(Pro-
Hyp-Gly)4(Asp-Hyp-Gly)4 that mimics collagen fibrils[135]. However, that peptide was 
only able to self-assemble into a soft hydrogel. For translational to clinical application, 
we needed a more robust hydrogel. We modified the O’Leary collagen-like-peptide by 
the addition of two extra amino acids – a glycine and a cysteine to allow covalent 
attachment to an 8-armed polyethylene glycol maleimide (PEG). The resulting CLP-
PEG hydrogels were transparent and mechanically strong enough for grafting into host 
corneas. The implants showed stable and functional integration into the corneas of 
mini-pigs. Corneal epithelial and stromal tissue as well as extracellular matrix 
components and nerves had grown into the implants. The CLP-PEG hydrogels were 
therefore able to function, as successful scaffolds that promoted regeneration, just like 
implants made from RHC. For translation into clinical application, the use of fully 
synthetic CLP-PEG hydrogels will avoid potential problems such as transmission of 
viruses and other pathogens. As substitutes of RHC, CLP-PEG is potentially easier to 
handle and would allow for future functionalization.  
 
 
  
  28 
  
6 CONCLUSION AND FUTURE PERSPECTIVES 
 
This thesis describes the results from interdisciplinary research, combining biomaterials 
research, tissue engineering and biology to find out a solution for corneal blindness. 
Biomaterials based on collagen, the major ECM component of the human body have 
been successfully stimulating tissue regeneration in clinical trials. Collagen derived 
from animal or human cadaveric sources, however, suffer from batch to batch 
heterogeneity and carry a risk of pathogen transmission. We avoided these problems by 
developing implants based on RHC: 
 
In particular, our optimized RHC-MPC implants stimulated the regeneration of corneal 
epithelium, stroma, and nerves in mini-pig corneas as well as corneas of HSK mice.  
These RHC-MPC implants were amenable to cutting with a femtosecond laser, and also 
to microcontact printing.  
 
Nevertheless, like native collagen, RHC is large, relatively inert and difficult to handle, 
leading to the development of a range of CLPs. A comparison of the versatility and 
functionality of CLP-PEG analogs showed that these hydrogels were comparable to that 
of full-length collagen as scaffolds for promoting regeneration in vivo in mini-pigs.   
 
I feel extremely fortunate to be a part of these interesting projects, and I am hopeful that 
these works will be helpful for removing the word blindness due to corneal disease. I 
also wish these works will be able to bring back light to millions of unprivileged people 
throughout the world.                  
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7 MY SCIENTIFIC CONTRIBUTION 
 
There is a colossal gap between the supply and demand for the good quality human 
donor corneas to replace diseased or damaged ones. I started the cornea research with 
the eagerness to solve the donor shortage problem by using artificial corneas. During 
the process, I have both optimized and developed new artificial corneas for future 
clinical use to combat conditions that are currently difficult to treat or deemed 
untreatable.  
 
For my thesis, I had optimized the RHC-MPC formulation that is now in clinical 
evaluation (ClinicalTrials.org identifier NCT02277054). I have also enhanced the 
mechanical properties of these implants by improving the elasticity using a BDDGE 
crosslinker. This resulted in a new version of the artificial cornea that would be more 
suturable and therefore easier for the surgeon to handle during transplantation.  
 
The production cost of RHC in yeast in a recombinant way is very expensive which 
ultimately increase the production costs of the artificial corneas made from these 
materials. In this thesis, I have developed an alternative artificial cornea that is made 
using collagen-like peptides. This fully synthetic implant will ultimately reduce the 
production cost of each artificial cornea. This will allow for potential scaling-up and 
large scale manufacturing of cost-efficient artificial corneas that can in the future be 
used to treat patients in developing nations.     
 
I feel extremely privileged to be a part of these challenging projects, and I am hopeful 
that these implants developed during the course of my Ph.D. work will help eradicate 
blindness due to corneal disease. My goal is to bring back light to millions of unsighted 
people worldwide, and in particular, those who are underprivileged and who would 
benefit from the scale-up of cost-effective artificial corneas.          
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8 POPULAR SUMMARY  
 
The cornea is an important part of the eye for vision. It is optically clear and functions 
like a window to the eye, letting light into the interior for vision. Corneal diseases are 
one of the major causes of blindness throughout the world. The main treatment still 
today for cornea blindness is the replacement of the diseased or damaged cornea with a 
human donor cornea by transplantation. However, the number of available donated 
corneas is severely limited compared to the demand in most countries. Even if donor 
corneas were readily available, cornea transplantation is not always successful as 
reactivation of diseases can occur after transplantation and can cause problems to the 
transplanted cornea. In addition, corneas with severe pathologies that include 
inflammation are often at high risk of rejection of the corneal grafts. As an attempt to 
solve the cornea shortage or rejection problem, an artificial corneal implant was being 
developed in this thesis. Crosslinked collagen and phosphorylcholine together were 
used to develop a transparent, hydrated implant with the shape and size of a human 
cornea. Collagen was used as the main ingredient because the human cornea is made up 
of mostly collagen. When transplanted into mini-pig corneas, the newly developed 
corneas were stable. The cells of the epithelium and stroma and nerves had regrown 
into the implants. The newly regenerated corneas showed functionality that approached 
that of normal corneas. We were also able to surface modify the materials using a 
printing technique. We printed stripes with a protein named fibronectin, and showed 
that thin stripes grew faster than thick stripes and unmodified surfaces. Although 
recombinant human collagen-based implants work well, its production is difficult and 
expensive. In addition, collagens are large and inert entities. In this thesis, we developed 
collagen-like peptide based corneal implants, which were easy and inexpensive to 
produce. The artificial cornea made from short peptide analogs of collagen was well 
tolerated in mini-pig corneas and promoted in-growth of host cells into the implants.  
The cells proliferated and produced new extracellular matrix to form a new cornea. Our 
all findings appear to be promising as potential implants to treat blindness and 
supplement the shortfall of human donor corneas.   
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